Ex vivo lung perfusion in lung transplantation: a case report

Yeginsu, Ali

doi:10.5606/tgkdc.dergisi.2016.11111

Turk Gogus Kalp Dama

2016

DOI: 10.5606/tgkdc.dergisi.2016.11111

|View full text |Cite

Ex vivo lung perfusion in lung transplantation: a case report

Ali Yeginsu¹

Abstract: ÖZVücut dışında akciğer perfüzyonu kullanılamayacak durumda olan donör akciğerlerinin fonksiyonlarını iyileştirmek için uygulanan bir yöntemdir. Yirmi dokuz yaşındaki donörde başlangıçta iyi olan kriterler zamanla bozuldu. Arteriyel kanda parsiyel oksijen basıncı 310 mmHg'den 230 mmHg'ye düştü. Akciğer nakli öncesinde vücut dışında akciğer perfüzyonu yapılmasına karar verildi. İki yüz on dakika vücut dışı akciğer perfüzyonu ile akciğerlerin durumu anlamlı şekilde iyileşti ve parsiyel oksijen basıncı 485 mmHg'y… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2021

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Comparison of Cilostazol and Naftidrofuryl in an Experimental Acute Ischemia-Reperfusion Model

Gülaştı

Yavuz

Arıkan

et al. 2020

Vasc Endovascular Surg

View full text Add to dashboard Cite

Introduction: Naftidrofuryl and cilostazol are drugs with proven efficacy in the treatment of claudication in peripheral vascular disease. In this experimental study, we evaluated the effects of naftidrofuryl and cilostazol in ischemia-reperfusion (IR) injury on various tissues. Materials and Methods: 40 male albino Wistar rats (8-12 weeks old, 250-350 g.) are randomly divided into 4 groups: Control (Group 1), sham (group 2), cilostazol pre-treatment (group 3), naftidrofuryl pre-treatment (group 4). During 21 days placebo is given to group 2, 12 mg/kg/day cilostazol is given to group 3, 50 mg/kg/day naftidrofuryl is given to group 4 orally. Ischemia and reperfusion are induced at the lower hind limb in Groups 2, 3 and 4. Ischemic muscle, kidney, liver, heart, brain and blood samples are obtained. The total antioxidant capacity, oxidant levels and oxidative stress index are studied for each group. Results: Both drugs have protective effects of remote organ injury following IR. Systemic effects are similar to each other, both have protective effects of IR injury. It showed no statistical significance in the total antioxidant capacity. Total oxidant levels are significantly affected by cilostazol in the heart (p < 0.01) and by naftidrofuryl in the liver (p < 0.01). The effect on oxidative stress was only significant with cilostazol on the heart (p < 0.01). Conclusion: Cilostazol and naftidrofuryl had beneficial effects in all tissues against tissue damage caused by IR injury. In ischemic muscle, kidney and heart cilostazol had improved outcomes comparing to naftidrofuryl. Naftidrofuryl had benefits over cilostazol in liver tissue.

show abstract

Comparison of Cilostazol and Naftidrofuryl in an Experimental Acute Ischemia-Reperfusion Model

Gülaştı

Yavuz

Arıkan

et al. 2020

Vasc Endovascular Surg

View full text Add to dashboard Cite

show abstract

Donor selection for lung transplant in Turkey: Is it necessary to wait for an ideal donor?

Vayvada¹,

Taşçı²

2021

Turk Gogus Kalp Dama

View full text Add to dashboard Cite

Background: The aim of this study was to evaluate the donor criteria used in lung transplantation in our clinic. Methods: A total of 55 cadaveric donors who were accepted for lung transplantation in our clinic between December 2016 and January 2019 were retrospectively analyzed according to ideal donor criteria. The donors were divided into two groups as ideal and non-ideal ones according to their age, partial pressure of oxygen in arterial blood, history of smoking, and ventilation day. Donor data, recipient characteristics and survival outcomes were evaluated. Results: Of 55 donors accepted for lung transplantation, 24 (43.7%) were ideal and 31 (56.3%) were non-ideal donors. The 90-day mortality and one-year survival rates were not significantly different between the two groups. The 90-day mortality was 25% in the ideal group and 22.6% in the non-ideal group (p=0.834). The one-year survival rates after lung transplantation were 64.5% versus 70.6% in the ideal and non-ideal groups, respectively (p=0.444). Conclusion: The whole clinical picture should be evaluated before accepting or rejecting donors for lung transplantation. The use of lung donors that do not meet the ideal criteria does not impair short- and mid-term results, compared to ideal lung donors. Strict implementation of donor criteria may prevent using suitable donors for lung transplantation. Use of non-ideal donors can reduce waiting list mortality.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Ex vivo lung perfusion in lung transplantation: a case report

Cited by 2 publications

References 6 publications

Comparison of Cilostazol and Naftidrofuryl in an Experimental Acute Ischemia-Reperfusion Model

Comparison of Cilostazol and Naftidrofuryl in an Experimental Acute Ischemia-Reperfusion Model

Donor selection for lung transplant in Turkey: Is it necessary to wait for an ideal donor?

Contact Info

Product

Resources

About